



Sodium Valproate Gastro-Resistant Tablets

IIP-EU-Development Line



Therapeutic indication: Epilepsy



150 mg Gastro-resistant tablets

One gastro-resistant tablet contains:
150 mg sodium valproate


Weight: 215 mg



300 mg Gastro-resistant tablets

One gastro-resistant tablet contains:
300 mg sodium valproate

Weight: 415 mg



600 mg Gastro-resistant tablets


One gastro-resistant tablet contains:
600 mg sodium valproate

Weight: 800 mg



We expressly point out that these dossiers or marketing authorisations cannot be used in countries where corresponding medicinal products or the application of such products are protected by patent.

Prescriptions of Antiepileptics (German Market)



Source: Schwabe, Paffrath Arzneiverordnungsreport

Product Advantages: High Quality IIP-EU-Development Line

- Dossiers for 150, 300 and 600 mg available
- cGMP compliant, European API manufacturer
- cGMP compliant, European contract manufacturer with high manufacturing capacities for sale peaks
- Competitive prices, high batch sizes
- Stability data for industrial scale batches available
- Homologous formulation for all strengths
- Stable and humidity-impermeable inert glass bottles
- BE-Study available for 300 / 600 mg, biowaiver for 150 mg
- Oral Solution, solution for injection, gastro-resistant tablets and sodium valproate/valproic acid prolonged-release film-coated tablets ⇒ Complete package for Sodium Valproate/ Valproic acid available
- Samples and exposé with scientific data available upon request



IIP – Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH

Management
Benzstraße 2a
63741 Aschaffenburg, Germany
Tel.: 00 49 - (0) 60 21-5 85 93-0
Fax: 00 49 - (0) 60 21-5 85 93-28
E-Mail: management@iip.de
www.iip.de

Regulatory affairs – Technical department
Benzstraße 2a
63741 Aschaffenburg, Germany
Tel.: 00 49 - (0) 60 21-5 85 93-0
Fax: 00 49 - (0) 60 21-5 85 93-28
E-Mail: regaffairs@iip.de
www.iip.de